Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $35.70

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have been assigned an average recommendation of “Moderate Buy” from the twelve analysts that are covering the company, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $35.70.

A number of research analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $34.00 target price on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, January 7th.

Hedge Funds Weigh In On Viridian Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Lord Abbett & CO. LLC purchased a new position in Viridian Therapeutics during the 3rd quarter worth approximately $8,917,000. JPMorgan Chase & Co. grew its holdings in shares of Viridian Therapeutics by 218.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company’s stock valued at $9,108,000 after acquiring an additional 274,641 shares in the last quarter. Barclays PLC grew its holdings in shares of Viridian Therapeutics by 113.1% during the 3rd quarter. Barclays PLC now owns 125,397 shares of the company’s stock valued at $2,851,000 after acquiring an additional 66,550 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of Viridian Therapeutics by 1,603.4% during the 3rd quarter. Principal Financial Group Inc. now owns 172,810 shares of the company’s stock valued at $3,931,000 after acquiring an additional 162,665 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Viridian Therapeutics by 89.1% during the 4th quarter. SG Americas Securities LLC now owns 31,085 shares of the company’s stock valued at $596,000 after acquiring an additional 14,644 shares in the last quarter.

Viridian Therapeutics Trading Down 2.6 %

NASDAQ:VRDN opened at $13.18 on Wednesday. Viridian Therapeutics has a 1 year low of $9.90 and a 1 year high of $27.20. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -3.06 and a beta of 0.81. The business has a fifty day moving average of $14.11 and a 200-day moving average of $18.11. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.05 million. Equities analysts predict that Viridian Therapeutics will post -4.03 earnings per share for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.